Haleon plc Discloses Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Aug 19, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, disclosure, 6-K
TL;DR
Haleon bought back some of its own stock on Aug 19, 2025. Standard disclosure.
AI Summary
Haleon plc announced on August 19, 2025, that it has completed a transaction involving its own shares. The filing, a Form 6-K, details this transaction as part of its reporting for the month of August 2025. This is a routine disclosure for foreign private issuers.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which can be relevant for investors monitoring share buybacks or other treasury stock movements.
Risk Assessment
Risk Level: low — This is a routine disclosure of a share transaction, not indicative of significant new risks.
Key Players & Entities
- Haleon plc (company) — Registrant
- August 19, 2025 (date) — Date of transaction and filing
- DRVW 2022 Ltd (company) — Former company name
FAQ
What type of transaction did Haleon plc engage in regarding its own shares?
Haleon plc engaged in a 'Transaction in Own Shares' as detailed in Exhibit 99.1.
When was this transaction in own shares announced or reported?
The transaction was reported on August 19, 2025.
What form is this SEC filing?
This is a Form 6-K, which is a Report of Foreign Private Issuer.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Does Haleon plc file annual reports under Form 20-F or Form 40-F?
Haleon plc files annual reports under cover of Form 20-F.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-19 06:01:53
Filing Documents
- a7942v.htm (6-K) — 33KB
- a7942v000.jpg (GRAPHIC) — 3KB
- 0001654954-25-009780.txt ( ) — 38KB
From the Filing
IN OWN SHARES a7942v UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of August 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 19 August 2025 - “Transaction in Own Shares”         99.1     Haleon plc:   Transaction in own shares   19 August 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 1,504,400 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 18 August 2025 18 August 2025 18 August 2025 Number of Shares purchased: 1,504,400 - - Highest price paid per Share (p): 359.8000 - - Lowest price paid per Share (p): 356.1000 - - Volume weighted average price paid per Share (p): 358.0459 - -   Following the settlement of the above, the Company's registered share capital   is 8,971,802,095 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,967,921,890 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/7938V_1-2025-8-18.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .      SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: August 19, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary